PMID: 3766528Nov 1, 1986Paper

Acute nonlymphocytic leukemia (M7 subtype) with erythrocytic internalization

American Journal of Hematology
S WoessnerL Florensa

Abstract

A case of acute nonlymphocytic leukemia of megakaryocytic lineage or M7 with a conspicuous phenomenon of erythrocytic internalization present in nearly 3% of the leukemic megakaryocytic precursors (LMP) is reported. The phagocytosis was detected at light microscopy and ultrastructural levels. The erythrocyte might have reached the interior of the LMP through cytoplasmic vacuoles that are connected with the extracellular space and that can be considered rudimentary equivalents of the demarcation membrane system (DMS). Erythrocytic internalization is not a specific feature of the mononuclear phagocytic system and can be misleading in the classification of undifferentiated blast cells.

References

Jan 1, 1978·Scandinavian Journal of Haematology·M D FoadiG D Pegrum
Jun 1, 1979·American Journal of Clinical Pathology·J H Fitchen, S Lee
May 1, 1979·British Journal of Haematology·G J den OttolanderR Bieger
Jan 1, 1975·Acta Haematologica·R NeuwirtováL Donner
Sep 1, 1980·British Journal of Haematology·M F MartelliM Rossodivita
May 1, 1982·British Journal of Haematology·D BevanM Greaves
Sep 1, 1981·British Journal of Haematology·C SultanF Reyes

❮ Previous
Next ❯

Citations

Jul 1, 1991·Cancer Genetics and Cytogenetics·C MarosiA Hagemeijer
Nov 1, 1989·Mayo Clinic Proceedings·K P WindebankE O Burgert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.